πŸ‡ΊπŸ‡Έ FDA
Patent

US 10266542

EZH2 inhibitors

granted A61PA61P35/00

Quick answer

US patent 10266542 (EZH2 inhibitors) held by Mirati Therapeutics, Inc. expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61P, A61P35/00